Emerging Threats & Priority Pathogens Treatments
The COVID-19 global health emergency has highlighted the need for vaccines to address novel infections, as its rapid spread has made vaccine development an urgent worldwide priority. While speed is of the essence, both scientific considerations for generation of effective and safe vaccines, and ease of deployment and administration en-masse are of paramount importance, especially given the huge scale at which such vaccines will be required to meet global demand.
SARS-CoV-2 is the latest in a series of viral threats to have emerged in the last 20 years, others of which include Ebola, MERS, Zika and Anthrax. Similarly, there are also a number of other emerging biological threats and priority pathogens that may affect the public or military personnel against which our ImplaVax® technology is uniquely positioned to address in partnership with global partners.